iatroX logo
brainstormaskiatroX
knowledge centreblog
Knowledge Centre / Neuroleptic Malignant Syndrome (NMS)

Neuroleptic Malignant Syndrome (NMS)

Recognition and management of antipsychotic drug reaction.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Mental HealthEmergency MedicineCritical Care

Clinical Guidelines

CKS: Bipolar Disorder - Antipsychotics
National
CKS: Psychosis and Schizophrenia - Adverse Effects
National
Evidence-based consensus guidelines for the management of catatonia and neuroleptic malignant syndrome
Local
Royal College of Psychiatrists Consensus Statement on High-Dose Antipsychotic Medication (CR190)
Local

Recent iatroX Q&As

  • What are the key clinical features to recognize Neuroleptic Malignant Syndrome (NMS) in a patient on antipsychotic medication?Updated: 8/22/2025
  • What immediate management steps should be taken for a patient diagnosed with NMS in a primary care setting?Updated: 8/22/2025
  • When should I consider referring a patient with NMS to secondary care for further management?Updated: 8/22/2025
  • What monitoring parameters should be established for a patient recovering from NMS after discontinuation of antipsychotic medication?Updated: 8/22/2025
askiatroX
privacytermshow it workscpdinsights
Download on the App StoreGet it on Google Play